arrow
返回
A

Arthur T. Porter

United States Department of Defense

46H指数
224论文数
7.7K被引数
收录论文 30
发表时间
Rear surface isolated defect evolution in laser accelerated targets激光加速靶中的背表面孤立缺陷演化
err2025-12-01
err0
PREAI
errZulick, C.; Fontana, J.; Kehne, D.; Porter, A.; Weaver, J. L.; Velikovich, A. L.; Aglitskiy, Y.; Bates, J.; Karasik, M.; Schmitt, A. J.; Obenschain, S. P.
err分享
err收藏
Radiation necrosis after SRS for intracranial metastases from lung cancer: A retrospective review
err2019-04-01
err0
errOAAI
errSharma, A.; Mountjoy, L.; Butterfield, R.; Zhang, N.; Ross, H.; Schild, S.; Ashman, J.; Daniels, T.; Paripati, H.; Mrugala, M.; Vora, S.; Patel, N.; Zimmerman, R.; Sio, T.; Porter, A.
err分享
err收藏
IMPACT OF ULTRAHIGH BASELINE PSA LEVELS ON BIOCHEMICAL AND CLINICAL OUTCOMES IN TWO RADIATION THERAPY ONCOLOGY GROUP PROSTATE CLINICAL TRIALS
err2011-06-01
err14
errOAAI
errRodrigues, George; Bae, Kyounghwa; Roach, Mack; Lawton, Colleen; Donnelly, Bryan; Grignon, David; Hanks, Gerald; Porter, Arthur; Lepor, Herbert; Sandler, Howard
err分享
err收藏
BASELINE SERUM TESTOSTERONE IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER
err2010-12-01
err16
errOAAI
errRoach, Mack, III; Bae, Kyounghwa; Lawton, Colleen; Donnelly, B. J.; Grignon, David; Hanks, Gerald E.; Porter, Arthur; Lepor, Herbert; Venketesan, Varagur; Sandler, Howard
err分享
err收藏
IMPACT OF ULTRAHIGH BASELINE PSA LEVELS ON BIOCHEMICAL AND CLINICAL OUTCOMES IN TWO RADIATION THERAPY ONCOLOGY GROUP (RTOG) PROSTATE CANCER (PC) CLINICAL TRIALS
err2009-09-01
err0
PREAI
errRodrigues, G.; Bae, K.; Roach, M.; Lawton, C.; Donnelly, B.; Grignon, D.; Hanks, G.; Porter, A.; Lepor, H.; Sandler, H.
err分享
err收藏
err分享
err收藏
Ten year follow-up of RTOG 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
err2006-11-01
err4
PREAI
errHanks, G. E.; Bae, K.; Porter, A. T.; Grignon, D.; Brereton, H. D.; Venkatesan, V. M.; Horwitz, E. M.; Lawton, C.; Sandler, H. M.; Shipley, W. U.
err分享
err收藏
Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of radiation therapy oncology group protocol 92-02
err2006-11-01
err44
errOAAI
errValicenti, Richard K.; DeSilvio, Michelle; Hanks, Gerald E.; Porter, Arthur; Brereton, Harmar; Rosenthal, Seth A.; Shipley, William U.; Sandler, Howard M.
err分享
err收藏
Mass energy-absorption coefficients and mass collision stopping powers for electrons in tumors of various histologies
err1999-03-10
err11
PREAI
errMaughan, RL; Chuba, P; Porter, AT; Ben-Josef, E; Lucas, DR; Bjarngard, BE
err分享
err收藏
Suppression of W256 carcinosarcoma cell apoptosis by arachidonic acid and other polyunsaturated fatty acids
err1998-12-06
err61
PREAI
errTang, DG; Guan, KL; Li, L; Honn, KV; Chen, YQ; Rice, RL; Taylor, JD; Porter, AT
err分享
err收藏
err分享
err收藏
The elemental composition of tumors: Kerma data for neutrons
err1998-06-04
err45
PREAI
errMaughan, RL; Chuba, PJ; Porter, AT; BenJosef, E; Lucas, DR
err分享
err收藏
Hyperbaric oxygen therapy for radiation-induced brain injury in children
errCANCER
IF5.1
err1997-11-15
err130
PREAI
errChuba, PJ; Aronin, P; Bhambhani, K; Eichhorn, M; Zamarano, L; Cianci, P; Muhlbauer, M; Porter, AT; Fontanesi, J
err分享
err收藏